$74.18−3.48 (−4.48%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Inhibrx Biosciences (INBX) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
10 figures withheld by our checks. Each blank figure names its reason.
Business engineChoppy: revenue compounds ~−15.0%/yr (FY23→FY25), net margin −10773.5%.
The four lines that matter · FY23–FY25
Revenue ($M)▲550.0%
1.3
FY23→FY25CAGR −15.0%/yr
Net income ($M)—
−140.1
FY23→FY25CAGR —
Free cash flow ($M)▲34.1%
−129.8
FY23→FY25CAGR —
Diluted EPS—
−9.04
FY23→FY25CAGR —
What the income statement says · FY23–FY25
Where every revenue dollar goes · FY25 ($M)
-10773¢ of every revenue dollar becomes profit.
Margin trend · direction beats level Operating Net
Net margin -10773.5% is below the sector median. This filer reports no gross profit line, so that margin is not drawn.
The receipt · income statement · FY23–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | YoY | CAGR 23→25 |
|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||
Revenue | 2,000.0 | 1,300.0 | 200.0 | 1,800.0 | ▲550.0% | −15.0% |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | —A | —A | —A | —A | — | — |
Research & development | 100,431.0 | 113,028.0 | 203,743.0 | 191,640.0 | ▼44.5% | −23.2% |
Selling, general & admin | 27,303.0 | 23,297.0 | 127,905.0 | 29,381.0 | ▼81.8% | −11.0% |
Total operating expenses | 127,734.0 | 136,325.0 | 331,648.0 | 221,021.0 | ▼58.9% | −21.5% |
Operating incomefeeds ROC rank | −125,734.0 | −135,025.0 | −331,448.0 | −219,221.0 | ▲59.3% | — |
Other income, net | −15,921.0 | −5,028.0 | 2,019,022.0 | −20,503.0 | — | — |
Pretax income | −141,655.0 | −140,053.0 | 1,687,574.0 | −239,724.0 | — | — |
Income tax | 3.0 | 2.0 | 2.0 | 3.0 | ▲0.0% | −18.4% |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −141,658.0 | −140,055.0 | 1,687,572.0 | −241,361.0 | — | — |
| Per share | ||||||
Diluted EPSbuyback-sensitive | −9.06 | −9.04 | 112.62 | −20.48 | — | — |
Diluted shares (mn) | 15.72 | 15.49 | 14.98 | 11.78 | ▲3.4% | +14.6% |
| Margins | ||||||
Gross margin | —A | —A | —A | —A | — | — |
Operating margin | −6286.7% | −10386.5% | −165724.0% | −12178.9% | ▲155337.5pp | +1792.4pp |
Net margin | −7082.9% | −10773.5% | 843786.0% | −13408.9% | ▼854559.5pp | +2635.5pp |
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-03-19 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Inhibrx Biosciences' revenue last fiscal year?
Inhibrx Biosciences reported revenue of $1.3M in fiscal 2025, up 550.0% from fiscal 2024.
What was Inhibrx Biosciences' net income?
Inhibrx Biosciences reported net income of −$140.1M in fiscal 2025, a net margin of −10773.5%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

